Industry News

Centene Corp., which plans to add more than 1..."/>
Is Clayton emerging as the St. Louis region's new 'downtown'? [St. Louis Post-Dispatch]
Press Ganey Holdings, Inc., today announced that it will hold a conference call on Tuesday, August 2, 2016, at 8:30 a.m. Eastern Time to review the Company's second quarter 2016 financial results. A press release announcing the second quarter financial results will be issued after the close of market trading on Monday, August 1, 2016.. To participate in the company's live conference call and webcast, please dial 877-201-0168 using conference code number 28532174, or..."/>
Press Ganey Holdings, Inc. Announces Second Quarter 2016 Earnings Conference Call
Aclaris Therapeutics, Inc., a clinical-stage specialty pharmaceutical company, will visit the Nasdaq MarketSite in Times Square. In honor of the occasion, Dr. Neal Walker, President and CEO, will ring the Closing Bell."/>
Aclaris Therapeutics, Inc. (Nasdaq: ACRS) to Ring The Nasdaq Stock Market Closing Bell
Quality Systems, Inc. will release its fiscal 2017 first quarter operating results on Thursday, July 28, 2016 after market close, with a conference call to follow at 5:00 p.m. Eastern Time. Shareholders and interested participants may listen to a live broadcast of the conference call by dialing 866-900-9499 or 937-502-2136 for international callers, and referencing participant code 51021073 approximately 15 minutes prior to the call."/>
Quality Systems, Inc. to Host Fiscal 2017 First Quarter Results Conference Call
ITC Ltd has appointed Sanjiv Puri, a wholetime director of the company, as chief operating officer with immediate effect, the company said in a filing to the Bombay Stock Exchange. On 6 December, Puri took over as executive director from 6 December, replacing P.V. Before that, Puri was the president of ITC's packaged goods business that accounts for about 80% of ITC's business."/>
Sanjiv Puri, new ITC COO, seen as Deveshwar's successor [Mint, New Delhi]
Jaguar Animal Health, Inc., an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, foals, and high value horses, today announced positive topline results of two recently-completed studies to evaluate the safety and effectiveness of Neonorm™ botanical extract in piglets. The studies were sponsored by a Chinese business entity and took place..."/>
Jaguar Animal Health Announces Positive Preliminary Topline Results of Two Chinese-sponsored Farm Studies to Evaluate the Safety and Effectiveness of Neonorm Botanical Extract in Piglets
Cerecor Inc., a clinical-stage biopharmaceutical company developing treatments to make a difference in the lives of patients with neurological and psychiatric disorders, today announced that the Pharmacotherapies for Alcohol and Substance Use Disorders Consortium has provided a grant to Dr. Ronald Marcus to assess the efficacy of CERC-501, a selective kappa opioid receptor antagonist, separately and in combination with one of two anti-hypertensive drugs, in..."/>
Cerecor Announces Research Grant from the Department of Defense to Study CERC-501 in Animal Models for Co-Morbid Post-Traumatic Stress Disorder and Alcohol Use Disorder
Manhattan Scientifics, Inc. announced today that it has signed a $500,000 Joint Development Agreement with General Cable. The agreement calls for the design and development of nano-structured aluminum for wire and cable applications with a strong focus on overhead conductor for the transmission of power."/>
Manhattan Scientifics Signs Development Agreement with General Cable
DigiPath Labs, a subsidiary of DigiPath, Inc., an independent cannabis lab testing and media firm, is pleased to announce that it has signed a laboratory testing agreement with The Cannavative Group, a fully licensed medical cannabis cultivator and producer located in Washoe County, Nevada. DigiPath Labs will test all cannabis products grown and produced by The Cannavative Group for potency, terpenoids, moisture content, foreign matter, heavy metals,..."/>
DigiPath Labs Sign Cannabis Testing Agreement With The Cannavative Group
Syneron Medical Ltd., a leading global aesthetic device company, announced today that the PicoWay ® picosecond laser received U.S. Food and Drug Administration clearance for a new ultra-short 785 nm wavelength, which is the third FDA cleared wavelength for PicoWay. The new ultra-short 785 nm wavelength is the first of its kind in the aesthetic market, utilizing a titanium sapphire laser for the removal of blue and green inks, and will..."/>
Syneron Candela's PicoWay Picosecond Laser Receives U.S. FDA Clearance for Ultra-Short 785nm Wavelength
Fortress Biotech, Inc., launched the first two prescription products in its dermatology franchise, Luxamend™ Wound Cream and Ceracade™ Skin Barrier Emulsion. Both products will be showcased at the 2016 American Academy of Dermatology Summer Meeting to be held at the Hynes Convention Center in Boston, Massachusetts on July 28-31.. Claude Maraoui, President and CEO of Journey Medical Corporation, said,“ The..."/>
Journey Medical Corporation Launches Luxamend™ Wound Cream and Ceracade™ Skin Barrier Emulsion
Cerner’ s comprehensive suite of integrated health care information technology solutions to support clinical, financial and population health management initiatives, resulting in a Clinically Driven Revenue Cycle™ across the enterprise’ s acute hospitals and nearly 100 ambulatory facilities. “To advance our goal of providing excellent care..."/>
Covenant Health Selects Cerner’s Enterprise-Wide Clinical, Financial and Population Health IT System
Immuron Limited announces the availability of its presentation from RedChip’ s Small Stocks, Big Money Investor Conference. The replay of the Company’ s presentation and Q&A session can be viewed at http://www.redchip.com/events/9/small-stocks-big-money-investor-conference/imc. ax. During the presentation, Immuron’ s CEO, Thomas Liquard, provides an overview of Immuron’ s business and an update on multiple milestones achieved over the..."/>
Immuron Announces Availability of RedChip Conference Presentation
athenahealth, Inc., a leading provider of cloud-based services and mobile applications for medical groups and health systems, today announced its Merit-Based Incentive Payment System Guarantee, which aims to shield healthcare providers and practices from downward payment adjustments under the proposed Medicare reimbursement program of the same name. The guarantee comes months ahead of the Centers for Medicare and Medicaid Services’..."/>
Athenahealth Announces Industry’s First MIPS Guarantee
PharmaCyte Biotech, Inc., a clinical stage biotechnology company focused on developing therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box ®, announced today that during its upcoming shareholder call Chief Executive Officer Kenneth L. Waggoner will not only update shareholders on PharmaCyte’ s clinical trial development program and respond to questions submitted by shareholders, he..."/>
PharmaCyte Biotech Shareholder Call Update
Halozyme Therapeutics, Inc. today announced that it has resumed the enrollment and dosing of patients in its ongoing Phase 1 b trial evaluating its investigational new drug, PEGPH20, in combination with KEYTRUDA in patients with advanced non-small cell lung and gastric cancers under a revised clinical protocol. The revised protocol has been submitted to all institutional review boards and is pending feedback from the FDA."/>
Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Trial With KEYTRUDA
Innovus Pharmaceuticals, Inc.. The biotechnology and pharmaceutical industries have significantly underperformed the S&P 500 so far this year-- by 25.7% and 12.6%, respectively-- but there are many opportunities for investors willing..."/>
SECFilings.com Covers Innovus Pharmaceuticals' Upcoming FDA Decision, Robust Portfolio, and Improved Cash Reserves and Financials
Chembio Diagnostics, Inc. today announced that it has commenced an underwritten public offering of $10.0 million of common shares. In addition, the Company intends to grant the underwriters a 30- day option to purchase additional shares equal to up to 15% of the aggregate number of shares to be sold in the Offering to cover over-allotments, if any.. Craig-Hallum Capital Group LLC is acting as sole book-running manager for the proposed Offering."/>
Chembio Diagnostics Announces Proposed Public Offering of Common Shares
OptimizeRx Corp., a health technology software company whose premier content-delivery platform enables pharmaceutical companies to provide on-demand patient-care services, will hold a conference call on Monday, August 8, 2016 at 4:30 p.m. Eastern time to discuss results for the second quarter ended June 30, 2016. The financial results will be issued in a press release prior to the call.. OptimizeRx management will host the presentation,..."/>
OptimizeRx Corporation Sets Second Quarter 2016 Conference Call for Monday, August 8, 2016 at 4:30 p.m. ET
Zosano Pharma Corporation, an emerging CNS company focusing on providing rapid symptom relief to patients using the Company’ s proprietary transdermal delivery system, today announced the dosing of its first subject in its registration-enabling pivotal efficacy trial, of its M207 patch, formerly known as ZP-Triptan, for the treatment of acute migraine.. “I’ m extremely pleased to announce our first subject treated in the Zotrip trial."/>
First Subject Treated in Zosano Pharma’s Pivotal Efficacy Trial for M207 Patch for Acute Migraine
Growblox Sciences, Inc.. Since being appointed CEO just three months ago, I have confirmed that this Company is everything that I thought it might be, and more. In Growblox, I found a company with unlimited potential."/>
Letter To Growblox Sciences, Inc. Shareholders From Its CEO
PositiveID Corporation, a life sciences company focused on detection and diagnostics, announced today its FDA-cleared Caregiver ® non-contact thermometer outperformed a temporal artery thermometer in every category evaluated during a Veterans Affairs San Diego Healthcare System study of Post Anesthesia Care Unit patients.. In the evidence-based study of 40 patients, PACU nurses evaluated the Caregiver thermometer and a temporal artery..."/>
PositiveID’s Caregiver Non-Contact Thermometer Outperforms in Evidence-Based Study
Sensus Healthcare, Inc., a medical device company specializing in the treatment of non-melanoma skin cancers and other skin conditions, such as keloids, with superficial radiation therapy, today reported the separation of the 2,300,000 units issued in its underwritten initial public offering in accordance with their terms. Each unit will separate into one share of common stock, $0.01 par value per share, and a three-year warrant to..."/>
Sensus Healthcare, Inc. Units Separate; Trading of Common Stock and Warrants Commences

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Financials625 Articles
Consumer Discretionary564 Articles
Information Technology554 Articles
Industrials429 Articles
Health Care372 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.